tiprankstipranks

Individual - New Portfolio

Brad Edwards

Individual
Individual Investor
Ranked #171,577 out of 778,277 TipRanks' Investors
Success Rate
44%
85 out of 195
profitable transactions
Average Return
38.24%
Average return
per transaction
Share this portfolio:

Portfolio Gain

1-Month Return▲ 8.09%
6-Month Return-
12-Month Return-
YTD Return▲ 5.71%
Total Return▲ 8.48%

Best Trade

Opened at
Closed at
Gain▲ 4924.00%

Bio

Just a guy, dinking around, trying to make a little side scratch.

Performance

26.04%0-26.04%
▲ 9.79%
▲ 3.53%
Jun 2024
▲ 8.13%
▲ 1.21%
Jul 2024
▼ 13.14%
▲ 2.34%
Aug 2024
▲ 2.93%
▲ 2.10%
▲ 1.73%
Sep 2024
▲ 10.03%
▼ 0.89%
▼ 7.46%
Oct 2024
▲ 26.04%
▲ 5.96%
▲ 8.24%
Nov 2024
▲ 5.97%
▼ 2.41%
▲ 0.71%
Dec 2024
▲ 8.75%
▲ 1.00%
▲ 5.71%
Jan 2025
TipRanks AverageS&P 500Investor Portfolio
▲ 9.79%▲ 3.53%
▲ 8.13%▲ 1.21%
▼ 13.14%▲ 2.34%
▲ 2.93%▲ 2.10%▲ 1.73%
▲ 10.03%▼ 0.89%▼ 7.46%
▲ 26.04%▲ 5.96%▲ 8.24%
▲ 5.97%▼ 2.41%▲ 0.71%
▲ 8.75%▲ 1.00%▲ 5.71%

Recent Activity

Company Name
% of Portfolio
Return
No. of Transactions
Last Transaction
Date
Butterfly Network
0.42%
▲ 132.66%
5
Sell
Jan 03, 2025
SciSparc Ltd.
1.12%
▲ 130.13%
5
Sell
Jan 03, 2025
aTyr Pharma
0.77%
▲ 14.02%
4
Sell
Jan 03, 2025
Allurion Technologies
1.16%
▼ 37.12%
6
Buy
Jan 03, 2025
Allot
0.45%
▲ 66.92%
4
Sell
Jan 03, 2025
Opko Health
1.14%
▼ 5.28%
3
Buy
Jan 03, 2025
Vivid Seats
0.45%
▲ 29.99%
2
Sell
Jan 03, 2025
Cadiz
0.65%
▲ 14.62%
4
Sell
Jan 03, 2025
Scilex Holding Company
1.13%
▼ 4.65%
3
Buy
Jan 03, 2025
Denison Mines
0.55%
0.00%
1
Buy
Jan 03, 2025
Neumora Therapeutics, Inc.
0.66%
0.00%
1
Buy
Jan 03, 2025
Gain Therapeutics
0.48%
▲ 39.66%
3
Sell
Jan 02, 2025
Chemomab Therapeutics
0.76%
▲ 14.11%
4
Sell
Jan 02, 2025
Vaxart
0.62%
▲ 41.86%
2
Sell
Jan 02, 2025
Inuvo
0.43%
▲ 74.82%
2
Sell
Jan 02, 2025
Sangamo Biosciences
1.06%
▲ 10.18%
5
Buy
Dec 31, 2024
Standard Lithium Ltd
2.07%
▼ 47.94%
5
Buy
Dec 31, 2024
Clene
0.74%
▲ 20.89%
3
Sell
Dec 31, 2024
Biodesix
0.77%
▲ 13.79%
5
Sell
Dec 31, 2024
SatixFy Communications
0.48%
▲ 49.05%
3
Sell
Dec 31, 2024